AzTrials
AzTrials

DehydrationNCT06368765

Oral Rehydration Solution and Dehydration Recovery

A study testing Oral Rehydration Solution (ORS) and Water in people with Dehydration, run by Abbott Nutrition at 1 site in United States.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

This is a prospective, randomized, controlled, blinded, crossover, study to evaluate the effects of an oral hydration solution. Read more about this study

Who is it for?
Ages 18 to 40 yearsHealthy volunteers can take part
Conditions the study is for
Dehydration
What is being tested?
Oral Rehydration Solution (ORS) and Water
Type of treatment
Pill or oral medicine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
9 participants
Where
1 siteUnited States
Study dates
8 Jul 2024to 17 Oct 2024
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 40 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Participant is 18 to 40 years of age.
  • Participant has a body mass index (BMI) ≥ 18 and ≤ 30 kg/m2
  • Participant reports having a moderate to heavy sweat rate when physically exerted or in extreme heat.
  • Participant is male or non-pregnant, non-lactating female, at least 6 weeks postpartum prior to screening visit.
  • Participant has a systolic blood pressure of < 130 mm Hg and a diastolic blood pressure < 90 mm Hg, without the use of anti-hypertensive medications.
  • Participant reports no predisposing cardiovascular conditions.
Show all 14Show fewer
  • If female, participant has a regular menstrual cycle.
  • Participant is willing to consume grape-flavored beverages during the study.
  • If participant is on chronic medication, the dosage must be constant for at least 2 months prior to first study visit and able to maintain medication type and dose throughout duration of study.
  • Participant is weight-stable for the two months prior to screening visit
  • Participant has voluntarily signed and dated an informed consent form (ICF), approved by an IRB, and provided applicable privacy regulation authorization prior to any participation in the study.
  • Participant has no known intolerance or allergy to ingredients in study products.
  • Participant is willing to refrain from using saunas or hot tubs for the duration of the study.
  • Participant is able and willing to follow study procedures and complete any forms or assessments needed during the study.

Who cannot join

  • Participant is a current, and including the past 8 weeks, participant in a weight-conscious sport such as but not limited to wrestling, powerlifting, boxing, rowing, gymnastics or any martial arts, with participation defined as ≥ 3x weekly training.
  • Participant is currently, and for the past 4 weeks or longer: running >40 miles per week on average, cycling >80 miles per week on average or swimming >20,000 yards per week on average.
  • Participant is participating in another study that has not been approved as a concomitant study
  • Participant has used a sauna in the past 4 weeks.
  • Participant uses any form of tobacco or nicotine, or other controlled substance not prescribed by a physician.
  • Participant has previous history with heat illness or injury that resulted in a visit to a medical center in the past 12 months.
Show all 16Show fewer
  • Participant has an eating disorder, severe dementia or delirium, history of significant neurological or psychiatric disorder, alcoholism, substance abuse or other conditions that may interfere with study product consumption or compliance with study protocol procedures.
  • Participant is currently taking or has taken antibiotics within 6 weeks of enrollment.
  • Participant is currently taking or has taken a diuretic within 1 week of enrollment.
  • Participant has been diagnosed with the following according to self-report:
  • Recent or current acute or chronic infections including but not restricted to respiratory infections, diarrhea, Hepatitis B or C, HIV infection or tuberculosis
  • Severe gastrointestinal disorders such as celiac disease, short bowel syndrome, pancreatic insufficiency, or cystic fibrosis
  • Metabolic [including diabetes], renal, hepatic, or respiratory disease
  • Active malignancy
  • Polycystic ovary disease
  • Any other clinically significant medical condition, which in the investigator's opinion, makes him or her unsuitable for inclusion in the study.

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Finlay Research

    Miami, Florida, 33126

Other trials in United States

About this study

Official title: Effects of Oral Rehydration Solution on Dehydration Recovery in Adults

This is a prospective, randomized, controlled, blinded, crossover, study to evaluate the effects of an oral hydration solution.

Conditions
Dehydration
Being tested
Oral Rehydration Solution (ORS), Water
Medical subject headings
Dehydration

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Oral Rehydration Solution (ORS)Other

    Participants will be administered the ORS during one of the study visits

  • WaterOther

    Participants will be administered water during one of the study visits

Study groups in NCT06368765
Study groupRoleWhat they receive
Oral Rehydration SolutionExperimentalOral rehydration solution with carbohydrate
Receives: Other: Oral Rehydration Solution (ORS)
WaterExperimentalWater with flavor
Receives: Other: Water

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Plasma Volume

    Calculated Change in Plasma Volume

    Measured: Through Study completion, an average of 2 weeks

Secondary outcomes (6)
  1. Body Mass

    Change in Body Mass

    Measured: Through Study completion, an average of 2 weeks

  2. Hydration Status Urine

    Change in Urine Osmolality

    Measured: Through Study completion, an average of 2 weeks

  3. Blood Biomarker - Plasma Osmolality

    Change in Plasma Osmolality

    Measured: Through Study completion, an average of 2 weeks

  4. Blood Biomarker - Plasma Electrolyte Concentration

    Change in Electrolyte Concentration

    Measured: Through Study completion, an average of 2 weeks

  5. Blood Biomarker - Plasma Glucose Concentration

    Change in Plasma Glucose Concentration

    Measured: Through Study completion, an average of 2 weeks

  6. Body Temperature

    Change in degrees Celsius

    Measured: Through Study Completion, as average of 2 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted16 Apr 2024
  2. Study start8 Jul 2024
  3. Primary completion17 Oct 2024
  4. Study completion17 Oct 2024

Why it stopped: Change in Research Focus

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Other
Allocation
Randomised
Intervention model
Crossover
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
9 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06368765
Sponsor's protocol ID
BL72
Status last verified
Feb 2025
First submitted
12 Apr 2024
Last updated
28 Feb 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Oral Rehydration Solution (ORS) and Water in people with Dehydration, run by Abbott Nutrition at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 14 inclusion and 16 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 28 Feb 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study was stopped early (reason given: Change in Research Focus). Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Plasma Volume (time frame: Through Study completion, an average of 2 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Feb 2025.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in